Research-to-care Continuum: Small Group Discussion Post 2

Biomarkers will continue to tease out subgroups of disease populations, will this save costs if we don’t use it in those who is doesn’t work for? But what can you do for those patients? Our culture is that you have to do something!!! So, do we need ot look more at what other interventions can do, such as lifestyle interventions? How can we incorporate that into clinical trials and research in general. Ideally the research-care continuum would not neglect those for who a treatment does not work for, but seek to figure out WHY it doesn’t work for them, and help us learn what we CAN do for them.